Cargando…

Fusion Proteins CLD and CLDmut Demonstrate Potent and Broad Neutralizing Activity against HIV-1

HIV-1 envelope glycoprotein (Env) interacts with cellular receptors and mediates virus entry into target cells. Blocking Env-receptor interactions represents an effective interventional strategy for developing HIV-1 entry inhibitors. We previously designed a panel of CD4-linker-DC-SIGN (CLD) constru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Ming, Xiao, Yingying, Du, Tao, Hu, Huimin, Ni, Fengfeng, Hu, Kai, Hu, Qinxue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323411/ https://www.ncbi.nlm.nih.gov/pubmed/35891347 http://dx.doi.org/10.3390/v14071365

Ejemplares similares

Broad neutralization coverage of HIV by multiple highly potent antibodies
por: Walker, Laura M., et al.
Publicado: (2011)

Broad and potent neutralization of HIV-1 by human-llama fusion antibodies derived from immunized llamas
por: McCoy, LE, et al.
Publicado: (2012)

CLD - A Detector Concept for the FCC-ee
por: Bacchetta, Nicola, et al.
Publicado: (2019)

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
por: Schoofs, Till, et al.
Publicado: (2019)

Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization
por: McCoy, Laura E., et al.
Publicado: (2012)

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
por: Schommers, Philipp, et al.
Publicado: (2020)

Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies
por: Julien, J, et al.
Publicado: (2012)

Novel vomputational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies
por: Evans, MC, et al.
Publicado: (2012)

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
por: Huang, Jinghe, et al.
Publicado: (2012)

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
por: Tang, Aimin, et al.
Publicado: (2019)

Whipple's Pancreatoduodenectomy in the Background of Chronic Liver Disease (CLD): An Institutional Experience
por: Ray, Samrat, et al.
Publicado: (2021)

Broadly neutralizing antibodies target the coronavirus fusion peptide
por: Dacon, Cherrelle, et al.
Publicado: (2022)

Broadly neutralizing antibodies target the coronavirus fusion peptide
por: Dacon, Cherrelle, et al.
Publicado: (2022)

A broad and potent neutralization epitope in SARS-related coronaviruses
por: Yuan, Meng, et al.
Publicado: (2022)

A broad and potent neutralization epitope in SARS-related coronaviruses
por: Yuan, Meng, et al.
Publicado: (2022)

Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents
por: Cao, Yunlong, et al.
Publicado: (2022)

Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies
por: Yuan, Meng, et al.
Publicado: (2019)

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface
por: Huang, Jinghe, et al.
Publicado: (2014)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B′ Infected Plasma Donor with Broadly Neutralizing Activity
por: Hu, Yuanyuan, et al.
Publicado: (2021)

Broadly Neutralizing Antibodies for HIV Eradication
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth
por: van Dorsten, Rebecca T., et al.
Publicado: (2021)

Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants
por: Svilenov, Hristo L., et al.
Publicado: (2022)

Immunofluorescent Detection of Two Thymidine Analogues (CldU and IdU) in Primary Tissue
por: Tuttle, Alex H., et al.
Publicado: (2010)

Four novel mutations in the lactase gene (LCT) underlying congenital lactase deficiency (CLD)
por: Torniainen, Suvi, et al.
Publicado: (2009)

CRISPR library designer (CLD): software for multispecies design of single guide RNA libraries
por: Heigwer, Florian, et al.
Publicado: (2016)

A Cross-Sectional Study of the Haematological Profile of Patients With Chronic Liver Disease (CLD)
por: Joshi, Deepika, et al.
Publicado: (2023)

bNAber: database of broadly neutralizing HIV antibodies
por: Eroshkin, Alexey M., et al.
Publicado: (2014)

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
por: Walls, Alexandra C., et al.
Publicado: (2021)

P04-53 LB. Potent and broad HIV-specific neutralizing antibodies in infants are not associated with prevention of mother to infant HIV transmission
por: Lynch, J, et al.
Publicado: (2009)

HIV vaccine development and broadly neutralizing antibodies
por: Greenspan, Neil S., et al.
Publicado: (2015)

The expanding array of HIV broadly neutralizing antibodies
por: McCoy, Laura E.
Publicado: (2018)

Broadly Neutralizing Antibodies for HIV-1 Prevention
por: Walsh, Stephen R., et al.
Publicado: (2021)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals
por: Walker, Laura M., et al.
Publicado: (2010)

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
por: Shingai, Masashi, et al.
Publicado: (2014)

Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals
por: Cheedarla, Narayanaiah, et al.
Publicado: (2017)

Pharmacotherapies for fatigue in chronic liver disease (CLD): a systematic review and meta-analysis (protocol)
por: Effiong, Andem, et al.
Publicado: (2018)

Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
por: Landais, Elise, et al.
Publicado: (2018)

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
por: Pinto, Dora, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hd61c40tj72grv0127qdt4mjvp